Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

9.370 +0.210 (+2.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,123,716
Open 9.330
Bid (Size) 9.380 (1)
Ask (Size) 9.890 (39)
Prev. Close 9.160
Today's Range 9.205 - 9.640
52wk Range 7.610 - 24.46
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. 
Via InvestorPlace
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
From Vir Biotechnology, Inc.
Via Business Wire

Performance

YTD
-10.85%
-10.85%
1 Month
-11.81%
-11.81%
3 Month
+1.41%
+1.41%
6 Month
-9.38%
-9.38%
1 Year
-60.70%
-60.70%

More News

Read More
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
Via Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
Via Benzinga
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
From Vir Biotechnology, Inc.
Via Business Wire
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Via Benzinga
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
From Vir Biotechnology, Inc.
Via Business Wire
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
From Vir Biotechnology, Inc.
Via Business Wire
VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
Via InvestorPlace
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
From Vir Biotechnology, Inc.
Via Business Wire
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Via InvestorPlace
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
Via InvestorPlace
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
From Vir Biotechnology, Inc.
Via Business Wire
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Via InvestorPlace
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.